HHS awards $20.5M for Biological Product Manufacturing to Seqirus Inc
Contract Overview
Contract Amount: $20,539,764 ($20.5M)
Contractor: Seqirus Inc
Awarding Agency: Department of Health and Human Services
Start Date: 2014-08-13
End Date: 2015-08-31
Contract Duration: 383 days
Daily Burn Rate: $53.6K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: CHANGES TO LINE ITEMS
Place of Performance
Location: EMERYVILLE, ALAMEDA County, CALIFORNIA, 94608
Plain-Language Summary
Department of Health and Human Services obligated $20.5 million to SEQIRUS INC for work described as: CHANGES TO LINE ITEMS Key points: 1. Contract awarded to Seqirus Inc. for biological product manufacturing. 2. Full and open competition was utilized for this award. 3. The contract has a duration of 383 days. 4. This award falls under the Office of Assistant Secretary for Preparedness and Response (ASPR).
Value Assessment
Rating: good
The award amount of $20.5 million for biological product manufacturing appears reasonable given the scope and duration. Benchmarking against similar contracts for specialized manufacturing services would provide a more definitive assessment.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The use of full and open competition suggests a robust price discovery process. This method allows multiple vendors to bid, potentially leading to more competitive pricing.
Taxpayer Impact: The competitive nature of the award is beneficial for taxpayers, as it aims to secure the best value for the government's investment in biological product manufacturing.
Public Impact
Ensures continued availability of critical biological products. Supports national preparedness and response capabilities. Contributes to the pharmaceutical manufacturing sector.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for price increases in future contract renewals.
- Dependence on a single vendor for critical manufacturing.
Positive Signals
- Successful execution of biological product manufacturing.
- Adherence to quality and safety standards.
Sector Analysis
This contract is within the healthcare and pharmaceutical manufacturing sector, which often involves high R&D costs and stringent regulatory requirements. Spending benchmarks for similar biological product manufacturing contracts can vary significantly based on product complexity and scale.
Small Business Impact
The data does not indicate whether small businesses were involved in this contract, either as prime contractors or subcontractors. Further analysis would be needed to assess small business participation.
Oversight & Accountability
The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is responsible for overseeing this contract. Standard procurement oversight processes should ensure accountability.
Related Government Programs
- Biological Product (except Diagnostic) Manufacturing
- Department of Health and Human Services Contracting
- Office of Assistant Secretary for Preparedness and Response Programs
Risk Flags
- Potential for sole-source justification in future renewals.
- Dependency on a single supplier for critical products.
- Uncertainty regarding long-term supply chain stability.
- Limited visibility into specific product and cost breakdown.
Tags
biological-product-except-diagnostic-man, department-of-health-and-human-services, ca, delivery-order, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $20.5 million to SEQIRUS INC. CHANGES TO LINE ITEMS
Who is the contractor on this award?
The obligated recipient is SEQIRUS INC.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).
What is the total obligated amount?
The obligated amount is $20.5 million.
What is the period of performance?
Start: 2014-08-13. End: 2015-08-31.
What is the specific biological product being manufactured and its criticality to national health security?
The specific biological product is not detailed in the provided data. However, given the awarding agency (ASPR), it is likely related to public health emergencies, pandemic preparedness, or the Strategic National Stockpile. Understanding the product's criticality is essential for assessing the true value and risk associated with this contract.
How does the per-unit cost of this manufacturing contract compare to industry averages for similar biological products?
Without specific details on the biological product and its production volume, a direct per-unit cost comparison is not feasible. The contract is a firm fixed price delivery order, suggesting that unit costs were established during negotiation. A detailed cost analysis would require access to the contract's pricing structure and relevant industry benchmarks.
What measures are in place to ensure the long-term supply chain resilience for this biological product beyond the current contract?
The current contract duration is 383 days. Long-term supply chain resilience would depend on future contracting strategies, potential diversification of manufacturers, and government investment in domestic production capabilities. ASPR likely has contingency plans, but specific details on long-term resilience are not provided.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY
Solicitation ID: 11100SOL00020
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 475 GREEN OAKS PKWY, HOLLY SPRINGS, NC, 27540
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $20,539,764
Exercised Options: $20,539,764
Current Obligation: $20,539,764
Contract Characteristics
Multi-Year Contract: Yes
Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: HHSO100201200014I
IDV Type: IDC
Timeline
Start Date: 2014-08-13
Current End Date: 2015-08-31
Potential End Date: 2015-08-31 00:00:00
Last Modified: 2024-10-15
More Contracts from Seqirus Inc
- TAS::75 0140::TAS Construction of Vaccine Manufacturing Facility — $1.3B (Department of Health and Human Services)
- TAS::75 0140::TAS Advance Development of Antigen-Sparing — $111.8M (Department of Health and Human Services)
- Drugs and Biologicals — $60.1M (Department of Health and Human Services)
- THE Purpose of This Task Order IS to Procure Influenza A/Astrakhan/3212/2020 (h5n8)-Like Master and Working Seed LOT for the Department of Health and Human Services Under Idiq Contract #75A50122D00004 During Base Period Year 1 — $30.7M (Department of Health and Human Services)
- THE Purpose of This Task Order IS to Procure a Influenza A(h2nx) Virus Vaccine Candidate(s) and Conduct Clinical Trial — $21.4M (Department of Health and Human Services)
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →